Sodium stibogluconate
- Generic Name
- Sodium stibogluconate
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C12H35Na3O26Sb2
- CAS Number
- 16037-91-5
- Unique Ingredient Identifier
- APJ6285Y89
- Background
Sodium stibogluconate is a medicine used to treat leishmaniasis and is only available for administration by injection. It belongs to the class of medicines known as the pentavalent antimonials. Sodium stibogluconate is sold in the UK as Pentostam (manufactured by GlaxoSmithKline). Widespread resistance has limited the utility of sodium stibogluconate, and in...
- Indication
For the treatment of various types of a protozoal infection called leishmaniasis, which may result from sandfly bites in tropical and temperate parts of the world. Also investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Associated Conditions
- Leishmaniasis, Mucocutaneous Leishmaniasis, Visceral Leishmaniasis
- Associated Therapies
- -
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 52
- Registration Number
- NCT05957978
- Locations
- 🇪🇹
University of Gondar, Gondar, Ethiopia
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- First Affiliated Hospital of Jinan University
- Target Recruit Count
- 5
- Registration Number
- NCT04906031
- Locations
- 🇨🇳
First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
- Conditions
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 439
- Registration Number
- NCT03129646
- Locations
- 🇪🇹
Abdurafi MSF Health Center, Ābderafī, Amhara, Ethiopia
🇸🇩El Hassan Centre for Tropical Medicine, Doka, Gedaref, Sudan
🇰🇪Kacheliba Hospital, Kapenguria, West Pokot, Kenya
Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India
- Conditions
- Interventions
- First Posted Date
- 2012-08-09
- Last Posted Date
- 2012-09-03
- Lead Sponsor
- Sarder Patel Medical College
- Target Recruit Count
- 100
- Registration Number
- NCT01661296
- Locations
- 🇮🇳
PBM Hospita and SP Medical College, Bikaner, Rajasthan, India
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
- Conditions
- Interventions
- First Posted Date
- 2009-11-11
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Access to Advanced Health Institute (AAHI)
- Target Recruit Count
- 45
- Registration Number
- NCT01011309
- Locations
- 🇵🇪
Instituto de Medicina Tropical"Alexander von Humboldt", Lima, Peru
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
- First Posted Date
- 2009-11-06
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 1
- Registration Number
- NCT01009502
- Locations
- 🇺🇸
Jesse Brown VHA Medical Center, Chicago, Illinois, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients
- Conditions
- Interventions
- First Posted Date
- 2009-10-16
- Last Posted Date
- 2011-03-28
- Target Recruit Count
- 63
- Registration Number
- NCT00996463
- Locations
- 🇦🇫
Leishmaniasis and Malaria Center, Mazar-e-Sharif, Balkh, Afghanistan
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
- Conditions
- Interventions
- First Posted Date
- 2008-03-05
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00629200
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of New Mexico, Albuquerque, New Mexico, United States
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
- Conditions
- Interventions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00498979
- Locations
- 🇺🇸
Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-04-06
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT00311558
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.